ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2070

Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis

Sarah Dyball1, John Reynolds2, Hector Chinoy3, Ariane Herrick1, Sahena Haque4, Ellen Bruce5, Sophia Naz6, Ben Parker7 and Ian N. Bruce8, 1The University of Manchester, Manchester, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3The University of Manchester, Sale, United Kingdom, 4Manchester Foundation Trust, Manchester, United Kingdom, 5Kellgren Centre for Rheumatology, Manchester, United Kingdom, 6Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, 7Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 8Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom

Meeting: ACR Convergence 2022

Keywords: quality of life, SF36, Sjögren's syndrome, Systemic lupus erythematosus (SLE), Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Poor health-related quality of life (HR-QoL) is well recognised within patients with connective tissue diseases (CTD). We hypothesised that subgroups of patients across the spectrum of CTD experience different HR-QoL patterns, and aimed to determine patient-level characteristics associated with different subgroups.

Methods: The Medical Outcomes Study Short-Form 36 (SF-36) questionnaire was used, and the eight continuous domains of the SF-36 questionnaire were derived which range from 0 to 100, with higher scores reflecting better HR-QoL. We used the “mclust 5.4.9” model-based clustering package in R V4.0.4 to identify latent profiles (LP) of patients with distinct HR-QoL patterns. Variances were equated and covariances fixed to zero. Missing values were imputed using methodology suggested by the SF-36 manual. Multivariable ordinal logistic regression was used to determine patient-level characteristics associated with each HR-QoL subgroup identified. Models were adjusted for ethnicity, sicca symptoms, fibromyalgia, anti-dsDNA antibodies and co-morbidities (using Charlson comorbidity index).

Results: Three-hundred and nine patients within the spectrum of CTDs completed the SF-36 questionnaire, (280 [90.6%] women, mean [SD] age 48.9 [12.9] years). There were 115 (37.2%) patients with lupus, 72 (23.3%) undifferentiated CTD, 56 (18.1%) primary Sjögren’s syndrome and 66 (21.4%) systemic sclerosis, myositis or an overlap syndrome (SSc-IIM). Three latent profiles were identified with poor (n=89; 28.8%), average (n=190; 61.5%) and excellent (n=30; 9.7%) HR-QoL (figure1). In multivariable models (table 1), LP were not associated with diagnostic grouping (Sjögren’s: OR 1.16 [95% CI 0.54-2.48]; undifferentiated CTD: OR 1.22 [95% CI 0.65-2.29]; SSc-IIM: OR 1.23 [95% CI 0.62-2.44]). There was no association with autoantibody profiles. Black ethnicity (OR 0.22 [95% CI 0.08-0.63]), Asian ethnicity (OR 0.39 [95% CI 0.19-0.78]), concomitant fibromyalgia (OR 0.40 [95% CI 0.21-0.78]), sicca symptoms (OR 0.57 [95% CI 0.35-0.92]) and multi-morbidity (OR 0.81 [95% CI 0.67-0.97]) were associated with the ‘poor’ HR-QoL LP.

Conclusion: Poor HR-QOL is common in patients with CTDs and patients can be clustered into distinct HR-QoL subgroups that is not primarily driven by their specific diagnosis or autoantibody profile. We identified a number of key demographic and clinical factors associated with poor HR-QOL in this population. These factors need to be addressed across the whole CTD spectrum as part of a holistic management approach aimed at improving overall patient outcomes.

Supporting image 1

Figure 1 – Latent profile analysis using eight domains of the SF_36 across connective tissue diseases (n=309). PF, physical function; RP, role physical; BP, body pain; GH, general health; VT, vitality; SF, social function; RE, role emotional; MH, mental health

Supporting image 2

Table 1 – Univariate and multivariable ordinal logistic regression to compare patient characteristics across LPs with LP1 (poor QoL) used as the reference category. Reference group: 1, SLE; 2, White. Multivariate analysis adjusted for ethnicity, sicca, fibromyalgia, anti-dsDNA antibodies and Charlson co-morbidity index. CTD, connective tissue disease; CCI, Charlson comorbidity index; dsDNA, double stranded DNA; OR, odds ratio; SSc-IIM, systemic sclerosis- idiopathic inflammatory myopathy syndrome.


Disclosures: S. Dyball, UCB, Eli Lilly; J. Reynolds, None; H. Chinoy, Eli Lilly, UCB; A. Herrick, None; S. Haque, None; E. Bruce, None; S. Naz, None; B. Parker, None; I. Bruce, AstraZeneca, Bristol-Myers Squibb(BMS), Eli Lilly, Aurinia, Janssen, GlaxoSmithKlein(GSK).

To cite this abstract in AMA style:

Dyball S, Reynolds J, Chinoy H, Herrick A, Haque S, Bruce E, Naz S, Parker B, Bruce I. Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/health-related-quality-of-life-across-the-spectrum-of-connective-tissue-diseases-a-latent-profile-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-related-quality-of-life-across-the-spectrum-of-connective-tissue-diseases-a-latent-profile-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology